Abstract
To therapeutically target disseminated tumor cells, while sparing the surrounding tissues, it is necessary to develop agents that interact with structures exposed selectively on the tumor cell surface. Members of the epidermal growth factor receptor family are commonly overexpressed in several tumor types and may serve as targeting structures. In this review we discuss the effects of EGFR and HER2 targeting agents that can deliver radioactive nuclides, i.e. antibodies and affibody molecules, on intracellular signaling. If the targeting agent, in addition to deliver radioactivity to the tumor, can sensitize the tumor for its effects by influencing signal pathways that regulate cell survival and proliferation this will probably be advantageous. We discuss the changes in intracellular signaling that occurs after treatment of cancer cells with the clinically approved monoclonal antibodies cetuximab (anti-EGFR), trastuzumab (anti-HER2) as well as HER2 targeted affibody molecules which are under preclinical development. An important defence mechanism for cells against radiation is to activate DNA repair systems and we also address how DNA repair proteins are regulated in response to radiation or EGFR activation.
Keywords: Affibody, akt, antibody, DNA-repair, EGFR, Erk, HER2, radiation, signal transduction, tumor targeting
Letters in Drug Design & Discovery
Title: Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors – Signal Transduction and DNA Repair
Volume: 3 Issue: 6
Author(s): Johan Lennartsson, Jorgen Carlsson and Bo Stenerlow
Affiliation:
Keywords: Affibody, akt, antibody, DNA-repair, EGFR, Erk, HER2, radiation, signal transduction, tumor targeting
Abstract: To therapeutically target disseminated tumor cells, while sparing the surrounding tissues, it is necessary to develop agents that interact with structures exposed selectively on the tumor cell surface. Members of the epidermal growth factor receptor family are commonly overexpressed in several tumor types and may serve as targeting structures. In this review we discuss the effects of EGFR and HER2 targeting agents that can deliver radioactive nuclides, i.e. antibodies and affibody molecules, on intracellular signaling. If the targeting agent, in addition to deliver radioactivity to the tumor, can sensitize the tumor for its effects by influencing signal pathways that regulate cell survival and proliferation this will probably be advantageous. We discuss the changes in intracellular signaling that occurs after treatment of cancer cells with the clinically approved monoclonal antibodies cetuximab (anti-EGFR), trastuzumab (anti-HER2) as well as HER2 targeted affibody molecules which are under preclinical development. An important defence mechanism for cells against radiation is to activate DNA repair systems and we also address how DNA repair proteins are regulated in response to radiation or EGFR activation.
Export Options
About this article
Cite this article as:
Lennartsson Johan, Carlsson Jorgen and Stenerlow Bo, Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors – Signal Transduction and DNA Repair, Letters in Drug Design & Discovery 2006; 3 (6) . https://dx.doi.org/10.2174/157018006777805503
DOI https://dx.doi.org/10.2174/157018006777805503 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Withdrawal Notice: Role of Zinc Oxide Nanoparticles Synthesized by Fenugreek Seeds Extract as Anticancer Agent: In Vitro and In Vivo Studies
Anti-Cancer Agents in Medicinal Chemistry Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Gastroenterological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medical Imaging Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Nano-Based Therapy for Treatment of Skin Cancer
Recent Patents on Anti-Infective Drug Discovery The Relevance of Microdialysis for Clinical Oncology
Current Clinical Pharmacology Polyamines in Gut Inflammation and Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: <i>In Silico</i> Drug Design and Medicinal Chemistry)
Current Topics in Medicinal Chemistry Novobiocin Analogs as Potential Anticancer Agents
Mini-Reviews in Medicinal Chemistry Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology